uniQure N.V. (NASDAQ:QURE) was upgraded by research analysts at ValuEngine from a “sell” rating to a “hold” rating in a research note issued on Monday, July 24th.
A number of other equities research analysts have also commented on the stock. Chardan Capital set a $13.00 price objective on shares of uniQure N.V. and gave the stock a “buy” rating in a report on Sunday, July 23rd. Jefferies Group LLC reissued a “hold” rating and issued a $8.00 price objective on shares of uniQure N.V. in a research report on Wednesday, April 12th. Oppenheimer Holdings, Inc. reissued an “outperform” rating and issued a $17.00 price objective on shares of uniQure N.V. in a research report on Friday, June 30th. Cowen and Company reissued a “buy” rating on shares of uniQure N.V. in a research report on Wednesday, May 24th. Finally, Zacks Investment Research downgraded shares of uniQure N.V. from a “buy” rating to a “sell” rating in a report on Wednesday, May 17th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $15.04.
Shares of uniQure N.V. (NASDAQ:QURE) opened at 8.41 on Monday. uniQure N.V. has a 52-week low of $4.72 and a 52-week high of $9.15. The stock has a 50 day moving average price of $7.71 and a 200-day moving average price of $6.20. The stock’s market capitalization is $214.96 million.
uniQure N.V. (NASDAQ:QURE) last posted its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.83) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.78) by $0.05. uniQure N.V. had a negative return on equity of 135.97% and a negative net margin of 203.99%. The business had revenue of $4.94 million during the quarter, compared to analyst estimates of $2.92 million. On average, equities research analysts anticipate that uniQure N.V. will post ($3.04) EPS for the current fiscal year.
In other news, insider Harald Petry sold 58,075 shares of the business’s stock in a transaction that occurred on Monday, June 26th. The shares were sold at an average price of $6.01, for a total value of $349,030.75. Following the completion of the transaction, the insider now directly owns 155 shares in the company, valued at approximately $931.55. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders sold a total of 173,460 shares of company stock valued at $1,042,986 over the last 90 days. Corporate insiders own 0.64% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in QURE. Oxford Asset Management bought a new position in uniQure N.V. during the first quarter worth about $100,000. Mangrove Partners acquired a new position in shares of uniQure N.V. during the second quarter valued at about $247,000. JPMorgan Chase & Co. boosted its position in shares of uniQure N.V. by 50.5% in the first quarter. JPMorgan Chase & Co. now owns 43,822 shares of the biotechnology company’s stock valued at $253,000 after buying an additional 14,702 shares during the period. Weiss Multi Strategy Advisers LLC boosted its position in shares of uniQure N.V. by 266.7% in the first quarter. Weiss Multi Strategy Advisers LLC now owns 55,000 shares of the biotechnology company’s stock valued at $318,000 after buying an additional 40,000 shares during the period. Finally, Paloma Partners Management Co boosted its position in shares of uniQure N.V. by 717.7% in the first quarter. Paloma Partners Management Co now owns 85,000 shares of the biotechnology company’s stock valued at $491,000 after buying an additional 74,605 shares during the period. Institutional investors and hedge funds own 29.00% of the company’s stock.
uniQure N.V. Company Profile
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for uniQure N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure N.V. and related companies with MarketBeat.com's FREE daily email newsletter.